Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-exploration study of pirtobrutinib in adults with primary immune thrombocytopenia
CTR20253341Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in immune thrombocytopenia (ITP), sponsored by Eli Lilly and Company. Started Sep 2025; status: active.
02
Drugs
pirtobrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20253341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253341.